Other
Therapeutics for Pulmonary Inflammatory disease
(2019)
Abstract
We are investigating the efficacy of both free and liposomal erythromycin in reducing inflammation in human alveolar cells. Using human A549 cells, we model inflammation and the immunomodulatory effects of erythromycin. We use an ELISA to determine exact concentrations of various mediators of inflammation including IL-8 and TNFα. Our ultimate goal is to understand the inflammatory process set forth by structural cells of the lungs in an effort to provide more options for relieving inflammation in the pulmonary system.
Disciplines
Publication Date
2019
Citation Information
Ali Azghani. "Therapeutics for Pulmonary Inflammatory disease" (2019) Available at: http://works.bepress.com/ali-azghani/97/